Study Of New Drug To Stimulate Immune System Of Cancer Victims: TGen, Scottsdale Healthcare, Mayo Clinic

The Translational Genomics Research Institute (TGen), Scottsdale Healthcare and Mayo Clinic are testing a new drug that could help cancer patients by stimulating the immune system. Clinical trials of the drug VTX-2337 are being conducted at TGen Clinical Research Services at Scottsdale Healthcare, a partnership of Phoenix-based TGen and Scottsdale-based Scottsdale Healthcare Corp., and at Mayo Clinic in Arizona. Dr.

More: continued here

Filed under: Clinical Trials on January 4th, 2009